Long intergenic non-protein coding RNA 2321 (LINC02321)

Long intergenic non-protein coding RNA 2321 (LINC02321) is a long non-coding RNA highly expressed in bladder cancer and positively correlated with poor prognosis[1][2]. LINC02321 promotes cell proliferation, migration, invasion, and resistance to cisplatin in bladder cancer cells, primarily by regulating the stability of RUVBL2 protein and by activating the VEGFA signaling pathway[1][2]. Mechanistically, LINC02321 appears to act as a molecular scaffold stabilizing RUVBL2 in the nucleus, thereby impacting DNA repair pathways and cell cycle progression[2]. High expression of LINC02321 has clear significance as a potential therapeutic target and as a prognostic biomarker in bladder cancer, although no drugs are known to directly target the RNA itself[1][2]. The biological implication of targeting LINC02321 in cancer therapy relates to modulating tumor progression and reversing chemoresistance, but safety concerns common to lncRNA-targeted therapies remain to be clarified[1][2].

Other names

CTD-3035D6.2LINC02321

Modulation of VEGFA signaling pathway (regulation of vascular endothelial growth factor A expression); Stabilization of RUVBL2 protein (affects RUVBL2 degradation, influencing DNA damage repair and cell cycle); Promotion of oncogenic pathways by acting as a molecular scaffold and regulator of protein stability